The tipped ladies of the medicine industry fell 30% Super Retail Wu Yunji floating deficit tens of millions

The market is expected to the day of the day medicine tipped ladies market and did not come on schedule. On the contrary, the day of the April 27 tipped ladies was a turning point in its share price plunge.　　As of June 29, the day of the close of the 7.52 yuan, the price of the tipped ladies is more than the 11.26 yuan in the closing price of a 33%. This trend is probably the original heavy warehouse betting on the Wu Yunji of the drug industry, the Super Retail unexpectedly.　　If the Wu Yunji does not fully ship, then in less than two months, Wu Yunji held shares of the market value of the impairment is close to tens of millions of dollars.　　Wu Yunji? Earlier, the Fang Pharmaceutical issued a notice, the company March 15 proposed the company's stock transactions to remove the risk of delisting and other special processing applications have been approved by the Shanghai Stock Exchange.　　On April 26, after a day of suspension, the company's stock short term from April 27 will be "*st Day" changed to "Day of medicine." China's general technology group in August 2008 became the company's new actual control of the people, *st finally in 2009 to achieve a smooth profit, the whole year to achieve operating income of 2.242 billion yuan, a year earlier growth of 22.34%,　　Owned by the listed company shareholders net profit of 10.485 million yuan, basic earnings per share of 0.025 yuan.　　2010 Quarterly, the company's first quarter to achieve the main business income of 746 million yuan, the creation belongs to the parent company net profit of 16.73 million yuan, the year-on-year increase of 722.66%. And the 2010-year quarter of the drug industry report shows that the Super Retail Wu Yunji to 3.0297 million shares of the company's top ten current shareholders fourth.　　In fact, Wu Yunji early in the third quarter of 2009 before the tipped ladies of the pharmaceutical industry. In addition to betting on the Wu Yunji, special attachment to the St shares, love in the "chestnuts out". 2010 Quarterly data show that Wu Yunji as "St" specialist name appeared in 9 St listed companies in the list of circulating shares.　　As at the end of the first quarter of 2010, Wu Yunji A total of 9th companies of nearly 60 million shares, negotiable market value of more than 286 million yuan.　　However, the tipped ladies after the side of the drug industry did not maintain the strong trend of upward, on the contrary, the two-tier market prices began to turn downward. Among them, April 29 and 30th, the two-day trading day, the shares plunged 9.97% and 7.77% respectively. Then, the next, the price of the pharmaceutical industry began to shake finishing. Into the late June, mutation. The price of the medicine industry in the next choice to break down. June 17 and 18th, the day of the drug industry continued to plunge, two consecutive trading days respectively plunged 5.6% and 9.58%.　　Subsequently, after a short break after four trading days, the day after the price of the drug stock diving, June 25, its share price deep adjustment of 8%, June 29 in the market adjustment led to another 8.18%.　　Bet on private offerings?　Days congenial gu a pharmaceutical industry researcher said that the day of the current pharmaceutical products mainly to raw materials and general medicine, product gross margin is lower.　"At present, the date of the pharmaceutical raw materials in the drug products to lincomycin, acetyl-pylori, the main guitar mildew." Because of the maturity of the doxycycline and the guitarist, the market growth space has been very small, and the growth of lincomycin will not be pleasantly surprised. Therefore, the company's non-public offerings is a future operation of a watch, the company is placed high hopes.　　The researcher said. And the day of the tipped ladies pharmaceutical industry with the release of its non-public offering plan show, the company intends to issue a reserve price of 8.75 yuan/share for the issue, to the group including the holding shareholder, not more than 10 targeted targeted distribution of 60 million to 100 million shares, raised not more than 1 billion yuan funds will be put into the "annual output of 10000 tons of vitamin B3 project　　, 1000 tons of vitamin K3 project, "annual production capacity of 500 tons of raw material drug project", "annual output of 300 tons of chlortetracycline project" and "holding subsidiaries Henan Pharmaceutical Co., Ltd. Logistics Base project" and other four projects. The researcher said that in recent years, the controlling shareholder of the actual control of the General technology group has been strong in the pharmaceutical industry will be stronger, and through mergers and acquisitions of Chinese medicine, China's emerging groups and other pharmaceutical assets. However, compared with the pharmaceutical industry, China Resources Group and the Chinese Medicine Group, the General Technology group's pharmaceutical business competitiveness still has a certain gap.　　Therefore, as the group's most powerful pharmaceutical industry entity, in order to enhance the overall strength of the pharmaceutical industry, narrowing the gap, the group's investment in the House will be a long-term trend. "In the future for the protection of additional and project implementation of the successful completion of the group will also give more support."　　The researcher thought.　　According to the time of the drug industry non-public offering plans disclosed, the group will be cash to subscribe to the private shares of the proportion of not less than 39.61%.　　According to GM's commitment to the company, the group will invest up to 3 billion yuan in 3-5 years, in accordance with the project schedule and business development needs, with additional registered capital, and not sell shares in the company for 10 years. This reporter noted that, plus the additional and before the investment of 500 million yuan in cash, the group investment funds are also less than 1 billion yuan.　　As a result, GM will still have to inject 2 billion yuan into the company in the future if it promises to do so. However, the future of the pharmaceutical industry can be successfully implemented Non-public offerings has yet to be further testing the market. As a result of the two-tier market, the price of the pharmaceutical industry has quickly broken below 8.75 of the issue. As of June 29 close, the date of the drug industry closed 7.52 Yuan, and 8.75 of the issue of the reserve price has 12.9% gap.